CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
Marcilio Jorge Fumagalli,
Luiza Antunes Castro-Jorge,
William Marciel de Souza,
Patrick Orestes de Azevedo,
Alana Witt Hansen,
Ricardo Tostes Gazzinelli,
Benedito Antônio Lopes da Fonseca,
Fernando Rosado Spilki,
Luiz Tadeu Moraes Figueiredo
Affiliations
Marcilio Jorge Fumagalli
Virology Research Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
Luiza Antunes Castro-Jorge
Virology Research Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
William Marciel de Souza
World Reference Center for Emerging Viruses and Arboviruses, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555-1019, USA
Patrick Orestes de Azevedo
Platform of Translational Medicine, Oswaldo Cruz Foundation, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
Alana Witt Hansen
Molecular Microbiology Laboratory, Healthy Science Institute, Feevale University, Novo Hamburgo, Novo Hamburgo 93525-075, Brazil
Ricardo Tostes Gazzinelli
Platform of Translational Medicine, Oswaldo Cruz Foundation, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
Benedito Antônio Lopes da Fonseca
Virology Research Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
Fernando Rosado Spilki
Molecular Microbiology Laboratory, Healthy Science Institute, Feevale University, Novo Hamburgo, Novo Hamburgo 93525-075, Brazil
Luiz Tadeu Moraes Figueiredo
Virology Research Center, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo 14049-900, Brazil
The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.
